论文部分内容阅读
目的观察早期应用普伐他汀对急性冠脉综合征(ACS)患者C反应蛋白(CRP)的影响。方法将50例入选患者随机分为观察组和对照组,观察组28例,除常规服用抗心肌缺血药物之外,同时服用普伐他汀,1片/d,对照组23例,常规服用抗心肌缺血药物,不服用降脂药,治疗前后检测CRP水平,2周为1疗程,共观察1个疗程。结果两组治疗前CRP水平比较无统计学意义(P>0.05),两组治疗后比较观察组对CRP水平影响显著优于对照组(P<0.01),对照组治疗前后比较无统计学意义(P>0.05)。结论早期应用普伐他汀治疗ACS能够显著降低血浆CRP水平,并无明显不良反应发生。
Objective To observe the effect of early pravastatin on C-reactive protein (CRP) in patients with acute coronary syndrome (ACS). Methods Fifty patients were randomly divided into observation group and control group. In the observation group, 28 patients were treated with pravastatin, 1 tablet / day, 23 patients in control group and routine taking anti-myocardial ischemia drugs Myocardial ischemia drugs, do not take lipid-lowering drugs, before and after treatment to detect CRP levels, 2 weeks for a course of treatment, were observed a course of treatment. Results There was no significant difference in CRP levels between the two groups before treatment (P> 0.05). The CRP level of the two groups after treatment was significantly better than that of the control group (P <0.01), while the control group had no significant difference before and after treatment P> 0.05). Conclusions Early use of pravastatin in treatment of ACS can significantly reduce plasma CRP levels, with no obvious adverse reactions.